You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme GBM high grade glioma a deadly and invasive brain tumor with no effective treatment Of the patients expected to be diagnosed with GBM this year most will succumb within a year There is an urgent demand for an efficac ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Hollow Fiber Catheter for Drug Delivery into the Prostate

    SBC: TWIN STAR TDS, LLC            Topic: 300

    DESCRIPTION provided by applicant The significance of the proposed research is based on the growing demand for healthcare resources to treat and manage prostatic disease particularly benign prostatic hyperplasia BPH and cancer Both the incidence and cost of treatment for BPH and its complications are growing rapidly with the aging U S population prostate cancer is the second leading cau ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Selection-driven plant metabolites for treatment of CNS diseases

    SBC: NAPROGENIX, INC.            Topic: 150

    DESCRIPTION provided by applicant This project aims to demonstrate that the evolution of plant biosynthetic pathways can be accelerated and driven to favor the synthesis of ligands which interact with a specific human target protein This is achieved by subjecting mutant plant cells to selection pressures favoring the survival of mutants with the phenotype of interest As an example this appro ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Naloxone Nasal Spray Development

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Point-of-Care HIV Antigen/Antibody Diagnostic Device

    SBC: Mbio Diagnostics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow of the widely used HIV rapid tests. Phase I research ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within a year. There is an urgent demand for an efficac ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Fetal Magnetocardiography Using Non-cryogenic Magnetic Field Sensors

    SBC: QUSPIN INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): While the number of diagnostic technologies available for adult applications continues to grow, there remains a paucity of technologies suitable for fetal evaluation. In particular, noninvasive assessment of fetal cardiac electrophysiology has not been routinely possible despite many decades of fetal ECG research. Recently, a number of groups have demonstrated ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Micro_patterned Surfaces for Reducing the Risk of Ventilator_Associated Pneumonia

    SBC: Sharklet Technologies Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Ventilator-associated pneumonia (VAP) is the most costly and second most common hospital-acquired infection (HAI), accounting for over 86% of hospital-acquired pneumonia (HAP). Some 300,000 HAP patients are treated annually in the U.S., at an estimated annual hospital cost of more than 1.5 billion. The current paradigm for preventing VAP has been to implement ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government